U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07533708) titled 'A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours' on April 02.
Brief Summary: This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
Study Start Date: May 25
Study Type: INTERVENTIONAL
Condition:
mCRPC or Advanced/Metastatic Solid Tumors
Intervention:
DRUG: HLX3902
HLX3902 will be administered as an intravenous (IV) infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Henlius Biotech
Disclaimer: Curated by HT Syndication....